BioArctic (BIOA) Pareto Healthcare Conference Presentation summary

Strategic focus and leadership in neurodegenerative diseases

• Concentrates on disorders with large unmet needs and patient populations, leveraging world-class R&D and collaborations.

• Recognized for developing Leqembi, the first fully approved disease-modifying therapy for Alzheimer's disease.

• Maintains a broad project portfolio in Alzheimer's, Parkinson's, ALS, and other CNS disorders.

• Utilizes highly selective antibodies and Brain Transporter technology to deliver biotherapeutics to the brain.

• Financially robust, supported by milestone payments and royalties, with 2023 operating profit of SEK 253M and cash position of ~SEK 0.9B.

Product pipeline and regulatory milestones

• Pipeline includes multiple candidates in various stages for Alzheimer's, Parkinson's, ALS, and Gaucher disease, many in partnership with Eisai.

• Leqembi (lecanemab) is approved in the US, Japan, China, South Korea, Great Britain, and other markets, with applications pending in several countries.

• Next-generation Alzheimer’s treatments using Brain Transporter technology are advancing, with two candidates in collaboration with Eisai.

• Exidavnemab is preparing for Phase 2a in Parkinson’s disease, with study start planned for Q4 2024.

Commercial performance and clinical data

• Leqembi royalties are rapidly increasing, with global Q2-24 sales at ¥6.3B (~$40M), a 120% increase over Q1-24.

• US expansion accelerated in May, with strong launches in Japan and China.

• 36-month data for lecanemab show increasing long-term treatment effect and maintained safety profile, with over 50% of early-stage patients showing improvement.

• No new safety findings and very low frequency of ARIA after the first 6 months of lecanemab treatment.